SPY337.44+4.64 1.39%
DIA280.04+2.85 1.03%
IXIC11,012.24+229.42 2.13%

Y-mAbs Therapeutics Q3 EPS $(0.7) Misses $(0.55) Estimate

Y-mAbs Therapeutics (NASDAQ:YMAB) reported quarterly losses of $(0.7) per share which missed the analyst consensus estimate of $(0.55) by 27.27 percent. This is a 66.67 percent decrease over losses of $(0.42) per share

Benzinga · -

Y-mAbs Therapeutics (NASDAQ:YMAB) reported quarterly losses of $(0.7) per share which missed the analyst consensus estimate of $(0.55) by 27.27 percent. This is a 66.67 percent decrease over losses of $(0.42) per share from the same period last year.